周一盘前，"妖股"脑再生科技（RGC）再度引发市场关注，股价大涨23.18%。该公司自年初以来累计涨幅已超过175倍，成为2025年美股市场表现最为亮眼的股票之一。
脑再生科技是一家主打中医脑科学的生物科技公司。尽管公司的核心技术——"神经再生"理论尚未得到中医界的广泛认可，但其独特的商业模式和市场表现却吸引了大量投资者的目光。公司声称将传统中医与前沿生物科技相结合，主要针对多动症（ADHD）和自闭症（ASD）等神经系统疾病进行研究和治疗。
分析人士指出，脑再生科技股价的暴涨主要源于几个因素：首先，公司在6月中旬实施了38:1的拆股计划，大幅提升了股票的流动性；其次，公司借助脑机接口概念和中医药政策红利，获得了投资者的青睐；最后，公司的小盘股特性和高度集中的股权结构（创始人持股86%）使得股价更容易被操纵。然而，也有专家警告，尽管该股表现亮眼，但投资者应当谨慎，注意其背后潜在的风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.